Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $270M | $284M | $332M | $419M | $430M | $542M | $667M | $675M | $701M | $726M |
| Revenue growth | — | 5.3% | 16.9% | 26.0% | 2.6% | 26.0% | 23.1% | 1.2% | 3.9% | 3.6% |
| Operating income | -$32.0M | -$24.9M | $15.9M | $10.5M | $46.4M | $89.9M | $60.0M | $87.7M | -$73.4M | $19.2M |
| Operating margin | -11.9% | -8.8% | 4.8% | 2.5% | 10.8% | 16.6% | 9.0% | 13.0% | -10.5% | 2.6% |
| Net income | -$37.9M | -$42.6M | -$471K | -$11.0M | $146M | $42.0M | $15.9M | $42.0M | -$99.6M | $7.03M |
| Net margin | -14.1% | -15.0% | -0.1% | -2.6% | 33.9% | 7.8% | 2.4% | 6.2% | -14.2% | 1.0% |
| EPS (diluted) | -$1.02 | -$1.07 | -$0.01 | -$0.27 | $3.33 | $0.92 | $0.34 | $0.89 | -$2.15 | $0.16 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $33.5M | $17.8M | $48.9M | $70.5M | $77.0M | $126M | $145M | $155M | $189M | $152M |
| Capital expenditures | $24.7M | $19.3M | $14.5M | $10.2M | $37.8M | $45.9M | $30.1M | $15.2M | $10.6M | $15.3M |
| Free cash flow | $8.74M | -$1.48M | $34.4M | $60.4M | $39.2M | $79.9M | $115M | $139M | $179M | $137M |
| Share buybacks | — | — | — | — | — | — | $0.00 | $0.00 | $25.0M | $148M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $35.9M | $54.1M | $133M | $78.2M | $100.0M | $586M | $104M | $153M | $277M | $159M |
| Total assets | $391M | $628M | $689M | $831M | $1.27B | $2.08B | $1.68B | $1.57B | $1.55B | $1.26B |
| Total liabilities | $172M | $349M | $368M | $476M | $655M | $1.34B | $906M | $704M | $775M | $572M |
| Long-term debt | $109M | — | — | — | — | — | $689M | $522M | $384M | $372M |
| Shareholders' equity | $219M | $279M | $321M | $355M | $620M | $730M | $775M | $870M | $778M | $693M |
| Retained earnings | -$346M | -$389M | -$388M | -$399M | -$254M | -$212M | -$149M | -$107M | -$206M | -$199M |
| Shares (wtd avg diluted) | 37.2M | 39.8M | 40.9M | 41.5M | 43.7M | 45.6M | 46.5M | 52.0M | 46.2M | 45.0M |
Every figure is extracted from Pacira BioSciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.